Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 5451.85
GNMSF's Cash to Debt is ranked higher than
100% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. GNMSF: 5451.85 )
GNMSF' s 10-Year Cash to Debt Range
Min: 10.54   Max: No Debt
Current: 5451.85

Equity to Asset 0.64
GNMSF's Equity to Asset is ranked higher than
73% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GNMSF: 0.64 )
GNMSF' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.64
Current: 0.64

0.21
0.64
F-Score: 5
Z-Score: 7.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 16.83
GNMSF's Operating margin (%) is ranked higher than
91% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. GNMSF: 16.83 )
GNMSF' s 10-Year Operating margin (%) Range
Min: -434.42   Max: 10760.13
Current: 16.83

-434.42
10760.13
Net-margin (%) 18.88
GNMSF's Net-margin (%) is ranked higher than
93% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. GNMSF: 18.88 )
GNMSF' s 10-Year Net-margin (%) Range
Min: -10124.65   Max: 16.93
Current: 18.88

-10124.65
16.93
ROE (%) 13.27
GNMSF's ROE (%) is ranked higher than
91% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. GNMSF: 13.27 )
GNMSF' s 10-Year ROE (%) Range
Min: -112.03   Max: 21.55
Current: 13.27

-112.03
21.55
ROA (%) 6.42
GNMSF's ROA (%) is ranked higher than
90% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. GNMSF: 6.42 )
GNMSF' s 10-Year ROA (%) Range
Min: -36.89   Max: 6.56
Current: 6.42

-36.89
6.56
ROC (Joel Greenblatt) (%) 552.77
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. GNMSF: 552.77 )
GNMSF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -675.71   Max: 284.86
Current: 552.77

-675.71
284.86
Revenue Growth (%) -0.50
GNMSF's Revenue Growth (%) is ranked higher than
75% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GNMSF: -0.50 )
GNMSF' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 331.5
Current: -0.5

0
331.5
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 98.40
GNMSF's P/E(ttm) is ranked higher than
86% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 98.40 )
GNMSF' s 10-Year P/E(ttm) Range
Min: 76.19   Max: 111.6
Current: 98.4

76.19
111.6
P/B 8.20
GNMSF's P/B is ranked higher than
67% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. GNMSF: 8.20 )
GNMSF' s 10-Year P/B Range
Min: 1.63   Max: 24.95
Current: 8.2

1.63
24.95
P/S 18.10
GNMSF's P/S is ranked higher than
74% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 20.06 vs. GNMSF: 18.10 )
GNMSF' s 10-Year P/S Range
Min: 3.08   Max: 42.95
Current: 18.1

3.08
42.95
EV-to-EBIT 95.31
GNMSF's EV-to-EBIT is ranked higher than
85% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 95.31 )
GNMSF' s 10-Year EV-to-EBIT Range
Min: 54.3   Max: 1407.3
Current: 95.31

54.3
1407.3
Current Ratio 3.37
GNMSF's Current Ratio is ranked higher than
71% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. GNMSF: 3.37 )
GNMSF' s 10-Year Current Ratio Range
Min: 1.3   Max: 3.37
Current: 3.37

1.3
3.37
Quick Ratio 3.37
GNMSF's Quick Ratio is ranked higher than
72% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. GNMSF: 3.37 )
GNMSF' s 10-Year Quick Ratio Range
Min: 1.3   Max: 3.37
Current: 3.37

1.3
3.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.10
GNMSF's Price/Net Cash is ranked higher than
87% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 80.40 vs. GNMSF: 8.10 )
GNMSF' s 10-Year Price/Net Cash Range
Min: 7.38   Max: 75.2
Current: 8.1

7.38
75.2
Price/Net Current Asset Value 8.10
GNMSF's Price/Net Current Asset Value is ranked higher than
85% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 41.80 vs. GNMSF: 8.10 )
GNMSF' s 10-Year Price/Net Current Asset Value Range
Min: 7.38   Max: 75.2
Current: 8.1

7.38
75.2
Price/Tangible Book 7.50
GNMSF's Price/Tangible Book is ranked higher than
74% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. GNMSF: 7.50 )
GNMSF' s 10-Year Price/Tangible Book Range
Min: 1.62   Max: 22.6
Current: 7.5

1.62
22.6
Price/DCF (Projected) 210.00
GNMSF's Price/DCF (Projected) is ranked higher than
59% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 210.00 )
GNMSF' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 210

Price/Median PS Value 2.10
GNMSF's Price/Median PS Value is ranked higher than
71% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. GNMSF: 2.10 )
GNMSF' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 5.01
Current: 2.1

0.48
5.01
Price/Graham Number 5.60
GNMSF's Price/Graham Number is ranked higher than
88% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNMSF: 5.60 )
GNMSF' s 10-Year Price/Graham Number Range
Min: 5.33   Max: 10.78
Current: 5.6

5.33
10.78
Earnings Yield (Greenblatt) 1.00
GNMSF's Earnings Yield (Greenblatt) is ranked higher than
55% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. GNMSF: 1.00 )
GNMSF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.8
Current: 1

0.1
1.8
Forward Rate of Return (Yacktman) -1.92
GNMSF's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. GNMSF: -1.92 )
GNMSF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.6   Max: -2.3
Current: -1.92

-6.6
-2.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GEN.Denmark, 0MGB.UK
Genmab A/S is a biotechnology company that utilizes antibody products. The company's treatments focus on cancer and other serious illnesses. The company has a pipeline of drugs in various stages of development and approval. The company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The company has a myriad of other products in development, pending completion and approval. The company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.
» More Articles for OTCPK:GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration Sep 10 2014
Major Shareholder Announcement Aug 25 2014
Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance Aug 13 2014
Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma Aug 11 2014
GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance... Jul 31 2014
Genmab reports Q2 Arzerra net sales GBP 12.8M Jul 23 2014
Second Quarter 2014 Net Sales Figures for Arzerra(r) Jul 23 2014
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma Jul 18 2014
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen Jul 14 2014
Johnson & Johnson to Make $25M Milestone Payment to Genmab Jul 08 2014
Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen Jul 07 2014
GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for... Jul 03 2014
Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint May 19 2014
Genmab says Janssen to start new Phase III study of daratumumab May 01 2014
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? Jan 02 2014
Why Genmab A/S (GNMSF) Stock Might be a Great Pick Dec 31 2013
Senesco: Near-Term Catalyst Could Double Shareprice Dec 27 2013
Genmab announces Phase II results of ofatumumab in Multiple Sclerosis Oct 10 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK